An interventional study of geriatric assessment and quality of life and Radiotherapy in Prostate Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 10 sites in France. Open to male participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Institut Cancerologie de l'Ouest · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest — 2 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · Institut Cancerologie de l'Ouest.
Among the 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest, this one is the only one that started in 2015, is one of 6 with no phase, and was the 3rd registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Men only
Institut Cancerologie de l'Ouest
Ages 18+
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 75 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3
First in 2011; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 96 across the 9 interventional studies, 60 across the 2 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators propose to carry out a prospective analysis of physical impact, psychological, cognitive and social of radiotherapy in all patients over 75 years bearer of localized prostate cancer with an indication of curative radiotherapy. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities . The quality of life of patients will be evaluated by the QLQ C30 (Quality of Life Questionnaire) European Organisation for Research and Treatment of Cancer (EORTC) before starting treatment, at the end of radiotherapy (2 months) and at 6 months. This short follow-up period seems appropriate in this elderly population and will allow an answer within 2 years to the problem raised in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Included patient must have a geriatric assessment before radiotherapy and 6 months later. Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.
Other: geriatric assessment and quality of life · Radiation: Radiotherapy
Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities . Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.
standard radiotherapy
Change in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Change in global health status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), scored from 0 to 100. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.
Time frame: From baseline to 2 months after radiotherapy
Change in Global Health Status Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Change in Global Health Status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status scale. Scores range from 0 to 100, with higher scores indicating better quality of life. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.
Time frame: From baseline to 6 months after radiotherapy
| Milestone | Geriatric Assessment and Quality of Life |
|---|---|
| Started | 208 |
| Completed | 208 |
| Not completed | 0 |
Change in global health status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), scored from 0 to 100. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.
| Participants | Geriatric Assessment and Quality of Life |
|---|---|
| Deterioration ≥ 10 points | 55 |
| Stable (±10 points) | 95 |
| Improvement ≥ 10 points | 40 |
Change in Global Health Status will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status scale. Scores range from 0 to 100, with higher scores indicating better quality of life. Changes between baseline and follow-up will be categorized as follows: deterioration defined as a decrease of 10 points or more, improvement defined as an increase of 10 points or more, and stability defined as changes within ±10 points.
| Participants | Geriatric Assessment and Quality of Life |
|---|---|
| Deterioration ≥ 10 points | 45 |
| Stable (±10 points) | 100 |
| Improvement ≥ 10 points | 36 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Geriatric Assessment and Quality of Life | 0/208 (0%) | 0/208 (0%) | 0/208 (0%) |
| Age, Customized(Participants) | Geriatric Assessment and Quality of Life |
|---|---|
| Overall — 75-79 year | 154 |
| Overall — 80-84 year | 49 |
| Overall — 85 year | 5 |
| Sex: Female, Male(Participants) | Geriatric Assessment and Quality of Life |
|---|---|
| Female | 0 |
| Male | 208 |
| Race and Ethnicity Not Collected(Participants) | Geriatric Assessment and Quality of Life |
|---|
| Region of Enrollment(Participants) | Geriatric Assessment and Quality of Life |
|---|---|
| France | 208 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Feb 2015, a primary completion of Feb 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2026, 9 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Cancerologie de l'Ouest →